Proposed acquisition of Life Sciences manufacturer Adaptas Solutions for $271m

IMI plc (“IMI” or the “Group”) announces the proposed acquisition of Adaptas Solutions (“Adaptas”) for an enterprise value of $271m (£202m1). Adaptas Solutions will become part of IMI’s Precision Fluid OEM Business Unit within IMI Precision Engineering. For the year ending 31 December 2021, Adaptas solutions is expected to generate revenues of c.$83m, with adjusted EBITDA of c.$17m (21% margin) and adjusted EBIT of c.$14m (17% margin), all on an IFRS basis. The acquisition reflects a purchase multiple of 16x adjusted 2021 EBITDA.

The proposed acquisition of Adaptas Solutions is fully aligned with IMI’s strategy and purpose [Breakthrough Engineering for a better world] and represents a highly attractive opportunity to deepen IMI Precision Engineering’s Life Science offering with a complementary product portfolio and strong relationships with leading global analytical instrument manufacturers. Closing is expected to take place before 31 December 2021, subject to customary merger filings.

Adaptas overview

Adaptas is a manufacturer of mission critical mass spectrometry subsystems and components, such as electron multipliers, filaments, power supplies and ion optic grids, as well as liquid handling and lab automation components. The company is based in Palmer, Massachusetts, USA and also has facilities in Pennsylvania USA, West Sussex in the UK, New South Wales in Australia, and Qidong in China. Jay Ray (CEO) and Laura Ray (SVP, Global Integration), family owners of the business prior to the investment by Ampersand Capital Partners in 2018, will remain with the business post-acquisition, to drive profitable growth of the combined Adaptas and IMI product portfolios.

Transaction highlights

  • The acquisition extends IMI Precision Engineering’s product portfolio further into Life Sciences – fully in-line with IMI’s stated strategy to develop into sustainable, profitable adjacencies.
  • Adaptas’ business model of developing customised technical solutions for its customers fits well with IMI’s operating model to solve customer problems in attractive, growth markets.
  • Adaptas enjoys strong and long-standing relationships with key global analytical instrument manufacturers. There are clear opportunities to broaden the market access of both Adaptas and IMI through the complementary customer bases and product ranges.
  • The sharing of best practice between the businesses will unlock operational efficiencies across both organisations.
  • Adaptas’ robust orderbook and project pipeline offer attractive and early growth opportunities.

The acquisition is forecast to be immediately earnings accretive, deliver a financial return in excess of IMI’s cost of capital by year three, and fully support IMI Precision’s delivery of its existing margin targets. The transaction fully aligns with the Group’s M&A guidelines and strict financial discipline. Proforma leverage (Net Debt / EBITDA) at the end of 2021 is expected to equal 1.5x, providing balance sheet capacity for further bolt-on opportunities.

Our strategy at IMI is all about delivering tremendous value by solving industry problems – and putting customers at the heart of our decisions and processes. We are delighted to partner with Adaptas whose business model and values are very similar to our own and I am excited to welcome all at Adaptas into the IMI team.”

Roy Twite, Chief Executive of IMI

Beth Ferreira, Divisional Managing Director of IMI Precision Engineering, commented:
“I am thrilled to welcome Adaptas. The business has fantastic products, and a market-leading position underpinned by deep relationships with global analytical instrument manufacturers. We are very much looking forward to working with Jay Ray, Laura Ray, and the whole Adaptas team to solve customer problems together and drive growth of our newly combined businesses.”

We have built an excellent business at Adaptas with a great team. I am very excited about continuing our strategy of growth through the development of innovative products and services for our customers, and to work together with our new colleagues at IMI to accelerate the success of our combined businesses.”

Jay Ray, CEO of Adaptas

Source:
  • https://www.imiplc.com/media/press-releases/proposed-acquisition-life-sciences-manufacturer-adaptas-solutions-271m

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Norgren Life Science. (2021, November 17). Proposed acquisition of Life Sciences manufacturer Adaptas Solutions for $271m. News-Medical. Retrieved on April 25, 2024 from https://www.news-medical.net/news/20211117/Proposed-acquisition-of-Life-Sciences-manufacturer-Adaptas-Solutions-for-24271m.aspx.

  • MLA

    Norgren Life Science. "Proposed acquisition of Life Sciences manufacturer Adaptas Solutions for $271m". News-Medical. 25 April 2024. <https://www.news-medical.net/news/20211117/Proposed-acquisition-of-Life-Sciences-manufacturer-Adaptas-Solutions-for-24271m.aspx>.

  • Chicago

    Norgren Life Science. "Proposed acquisition of Life Sciences manufacturer Adaptas Solutions for $271m". News-Medical. https://www.news-medical.net/news/20211117/Proposed-acquisition-of-Life-Sciences-manufacturer-Adaptas-Solutions-for-24271m.aspx. (accessed April 25, 2024).

  • Harvard

    Norgren Life Science. 2021. Proposed acquisition of Life Sciences manufacturer Adaptas Solutions for $271m. News-Medical, viewed 25 April 2024, https://www.news-medical.net/news/20211117/Proposed-acquisition-of-Life-Sciences-manufacturer-Adaptas-Solutions-for-24271m.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.